Jump to section
To accelerate biomedical innovation, by building the reference foundation model of biology that will unlock AI superpowers to the biomedical ecosystem.
Founded in 2024, Bioptimus is a company in the early stages of its mission to build an AI-powered foundation biology model. The biomedical space is becoming far more open to adopting new technology, and with an extensive pool of knowledge from former Google DeepMind and Owkin scientists, this could be a pivotal time for the company to make a change in the space.
By employing AI models trained on vast biological data, Bioptimus is working to unveil complex laws of biology that have so-far remained indecipherable. This comprehensive, deep understanding will be crucial for accelerating breakthroughs in both biomedicine and environmental science.
The Paris-based company has achieved a significant milestone by securing seed funding, which it plans to deploy in scaling operations and advancing its AI model. The exciting achievement will give the company a chance to showcase its potential to reshape the future of biomedicine and scientific innovation.
Freddie
Company Specialist at Welcome to the Jungle
Feb 2024
$35m
SEED
Rodolphe Jenatton
(CTO)Previously worked as a Senior Research Scientist at Google, and Senior Machine Learning Scientist at Amazon.
Zelda Mariet
(Principal Research Scientist)Worked through several roles at Google, most recently as a Research Scientist.
Eric Durand
(Deputy General Manager)Worked at Owkin as a SVP of Data Science, and spent 7 years at Novartis, most recently as the Director of Data Science.
Felipe Llinares-López
(Principal Research Scientist)Was a Senior Research Scientist at Google and worked as a Postdoctoral Researcher in Machine Learning and Computational Biology at ETH Zurich.
Jean-Philippe Vert
(Executive Chairman)Also works as the Chief R&D officer at Owkin, and is an Affiliate Professor at Mines Paris. Previously worked for Google as a Senior Staff Research Scientist.